Note: Ingredients listed on restricted chemical lists
EC/CAS
202-785-7/99-76-3
Name of the chemical
4-hydroxybenzoic acid, methyl ester
Concentration
N/A
EC/CAS
202-307-7/94-13-3
Name of the chemical
Propylparaben; propyl 4-hydroxybenzoate
Concentration
N/A
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
EC/CAS
9005-65-6
Name of the chemical
polyethyleneglycol sorbitan monooleate
Concentration
N/A
General Information
Version
4.0
Revision date
2012-03-02
Product name
DEPO-PROVERA; DEPO-PRODASONE; FARLUTAL; FARLUTAL DEPO; ONCO-PROVERA
Product Synonyms
Medroxyprogesterone Suspension, For Injection, IM
Icons in SDS
Company Information
company name
Pfizer Inc
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
GHS Information
Signal word
DANGER
Section 2
SECTION 2: Hazards identification
Appearance: White to off-white suspension
Signal word
DANGER
Hazard statements
May cause cancer. May damage fertility or the unborn child. Toxic to aquatic life with long lasting effects.
Additional information
Short Term: Not an eye irritant ; Not a skin irritant ; Not acutely toxic (based on animal data) . Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs, reproductive system, the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea). Known Clinical Effects: Adverse effects associated with therapeutic use of medroxyprogesterone acetate include menstrual irregularities, abdominal pain or discomfort weight changes, dizziness, headache, weakness or fatigue, and nervousness. Clinical use of this drug has caused loss of libido impotence development of male characteristics in the female fetus
EU Classification
EU Indication of danger: Toxic to reproduction: Category 1 Carcinogenic: Category 2 Dangerous for the Environment EU Hazard Symbols: _______________________________________________________________________________________________________ PZ01162 101 EU Risk Phrases: R45 - May cause cancer. R60 - May impair fertility. R61 - May cause harm to the unborn child. R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. Australian Hazard Classification
Hazardous Ingredients
Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
